|Year : 2018 | Volume
| Issue : 1 | Page : 35-38
The role of reactive oxygen species in screening anticancer agents
Xiaohui Xu1, Zilong Dang2, Taoli Sun3, Shengping Zhang1, Hongyan Zhang1
1 Department of Health Products Cosmetics and Medical Instrument, Lanzhou Institutes for Food and Drug Control, Lanzhou, Gansu, China
2 Department of Pharmacy, Frist Hospital of Lanzhou University, Lanzhou, Gansu, China
3 Key Laboratory Breeding Base of Hu'nan Oriented Fundamental and Applied Research of Innovative Pharmaceutics, College of Pharmacy, Changsha Medical University, Changsha, Hu'nan, China
|Date of Submission||24-Jan-2018|
|Date of Acceptance||14-Feb-2018|
|Date of Web Publication||26-Feb-2018|
Assoc. Prof. Shengping Zhang
Department of Health Products Cosmetics and Medical Instrument, Lanzhou Institutes for Food and Drug Control, Lanzhou 730000, Gansu
Source of Support: None, Conflict of Interest: None
Development of anticancer agents with high efficacy and low toxicity has always been a challenge in cancer therapeutics. Reactive oxygen species (ROS) are one of the most important physiological stimuli and have been correlated with several cancer conditions. Cancer cells adapt to new higher ROS environment. Meanwhile, elevated ROS render cancer cells vulnerable to oxidative stress-induced cell death. Anticancer drugs are involved in inhibiting and suppressing cancer progression through ROS-mediated cell death. Thus, it is useful to study the level of ROS generated by anticancer agents in cancer cells, while sparing the normal cells, which is one of the target methods to study the pharmacological properties of anticancer agents. In this review, we discuss the relation between ROS and anticancer agents, as well as the application of ROS in anticancer agents' activity screening.
Keywords: Anticancer agents' activity screening, cell apoptosis, cell cycle arrest, reactive oxygen species
|How to cite this article:|
Xu X, Dang Z, Sun T, Zhang S, Zhang H. The role of reactive oxygen species in screening anticancer agents. Cancer Transl Med 2018;4:35-8
|How to cite this URL:|
Xu X, Dang Z, Sun T, Zhang S, Zhang H. The role of reactive oxygen species in screening anticancer agents. Cancer Transl Med [serial online] 2018 [cited 2018 Dec 14];4:35-8. Available from: http://www.cancertm.com/text.asp?2018/4/1/35/226172
| Introduction|| |
Cancer, the second leading cause of death, is a major public health problem in the United States that needs immediate attention.,,, In this regards, through in vitro bioassays, various synthetic or natural compounds are screened for their potential anticancer activity. The ability of such tested compounds to inhibit the growth of cancer cells under in vitro condition indicates their possible potential in vivo anticancer activity. Reactive oxygen species (ROS), which includes superoxide anion, hydroxyl radical, hydrogen peroxide, singlet oxygen, and so on,,, are generated during cellular metabolism, primarily in mitochondria, as well as during cellular response to external factors including bacterial invasion. Oxidative stress-induced peroxidation has been associated with human cancer. Low levels of ROS has been observed in normal cells, while an increase in ROS generation has long been observed in cancer cells. Cancer cells are shown to have increased ROS levels in comparison to their normal counterparts. This is partly due to an enhanced metabolism and mitochondrial dysfunction in cancer cells. Concomitantly, to maintain ROS homeostasis and evade cell death, cancer cells increase their antioxidant capacity. Cancer cells in advanced stage tumors frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially modulate the development of these cells by controlling their ROS production. However, ROS act as a double-edged sword in cancer cells, on the one hand, ROS can promote pro-tumorigenic signaling, facilitating cancer cells proliferation, survival, and adaptation to hypoxia, on the other hand, ROS can promote antitumorigenic signaling and trigger oxidative stress-induced cancer cell death. Recent studies suggested that the biochemical activity of ROS on cancer cells could be exploited for therapeutic benefits. Effects of anticancer agents on ROS have been reported previously. These anticancer agents can induce ROS pathway activation which results in S-phase cell cycle arrest, but N-acetylcysteine (NAC), a ROS inhibitor, could effectively abrogate the S-phase arrest. Anticancer agents also block cancer cells at the S-phase by the downregulation of CDK1, CDK2, Cyclin A, and Cyclin B1 through ROS pathways. Caspases are crucial components of the apoptotic machinery in various cells, the activation of which is a central event in the process of apoptosis. Anticancer agents dramatically increase the expression of cleaved caspase-3, 8, 9, which is almost completely abolished by NAC. These findings indicate that anticancer agents induce apoptosis of cancer cells through the ROS-dependent activation of caspases. Many anticancer drugs promote oxidation of the tumor; to induce tumor cell death through increased ROS levels and to inhibit intracellular antioxidant enzyme system. Of course, there are also many pathways involved in the downstream of ROS and oxidative stress-induced cell activates. Hence, ROS exert oxidative stress and induce cell death through various signaling pathways, such as proliferation (protein tyrosine phosphatases, mitogen-activated protein kinase, and phosphoinositide 3-kinase); ROS homeostasis and antioxidant gene regulation (thioredoxin, peroxiredoxin, Ref-1, and Nrf-2); mitochondrial oxidative stress, apoptosis, and aging (p66Shc); iron homeostasis through iron–sulfur cluster proteins (IRE–IRP); and so on. In this review, we discuss the anticancer role of ROS, including the induction of either cell cycle arrest or apoptosis through its signaling pathways, and the application of ROS in the anticancer agents' activity screening.
| Anticancer Agents Exert Anticancer Activity Via Ros Signaling Pathways|| |
The role of reactive oxygen species signaling pathways in cancer cell-division cycle
The cell-division cycle consists of four phases: G1 phase, S phase, G2 phase, and M phase. Recently, it has become clear that ROS influences cell cycle progression. ROS can positively influence tumor cell proliferation and mediate cytotoxicity, while increase in ROS can reduce cancer cells proliferation by inducing cell cycle arrest. Recent studies found that anticancer agents could increase intracellular accumulation of ROS in cancer cells and induce cancer cell cycle arrest, which can be abolished by NAC, a ROS inhibitor., For instance, bortezomib induced an increase in intracellular ROS and on treatment with the ROS scavenger NAC a decrease in the number of cells in G2-M phase was seen. Similarly, daidzein retards G1/S cell cycle transition by regulating intracellular ROS in hepatoma cell line (BEL-7402). The study, along with other studies, also showed that ROS often controlled ubiquitination through phosphorylation, and that the process of phosphorylation is influenced by ROS.,, In general, ROS affect cell cycle progression by regulating gene transcription of cell cycle regulatory enzymes such as cyclins (CDKs and CKIs), while at the same time the course of transcription stimulates ROS production. The produced ROS can influence cell cycle progression through affecting phosphorylation and ubiquitination of cell cycle regulatory enzymes.
Reactive oxygen species signaling pathways induce cancer cells apoptosis
Cell apoptosis represents one of the hallmarks of the tumor cells death, which can be triggered by a variety of stimuli, including chemotherapeutic agents. Apoptosis is also related to activation of specific proteases, termed caspases. Apoptotic cell exhibits distinct morphological and biochemical features, such as chromatin condensation, membrane surface blebbing, DNA fragmentation, and so on. Deregulation of apoptotic process may lead to cancer cell formation and proliferation. ROS is generated within the cells during metabolic reactions, and hence its basal level is very high in cancer cells. ROS is targeted by few anticancer agents to bring about cancer cells apoptosis and inhibit proliferation.,, The aim of screening anticancer agents is to assess their ability to kill cancer cells, mainly through apoptosis, without harming normal cells. This ability to kill cancer cells is through contributing a novel redox system of regulatory control, superimposed on established growth signal pathways that mainly include tyrosine phosphorylation, some apoptosis regulating proteins, and the tumor necrosis factor/nerve growth factor receptors family. However, other mechanisms, such as ROS generation, appear to be equally important. For instance, the antioxidant NAC blocks apoptosis in some tumor cells, but anticancer agents induce apoptosis in some tumor cells. Some published studies over the past years, both in cell culture and animal models, have demonstrated the ability of anticancer agents to act on ROS in inducing apoptosis in cancer cells.
| Reactive Oxygen Species in Screening Anticancer Agents' Activity|| |
The level of ROS generated by a target compound may decide if it can be translated to clinical application. Almost all types of cancer cells show abnormally elevated levels of ROS as well as equally elevated expression of antioxidant agents to neutralize the ROS. The presence of ROS creates an environment of higher intrinsic oxidative stress. All therapeutic approaches, either conventional or alternative, target either one or more of these acquired properties by disturbing the redox status of the cancer cells, to inhibit proliferation or to cause cell damage and cell death. Anticancer agents are shown to induce apoptosis in human cancer cells, both in vitro and in vivo, through promoting ROS signaling pathways, which demonstrate their potential in clinical treatment. Anticancer agents can not only directly increase ROS generation but also weaken the antioxidant defense system of cancer cells, leading to cell cycle arrest and cell apoptosis. Hence, ROS are regarded as the target of the anticancer agents in cancer therapy. On the contrary, this makes the cancer cells vulnerable to agents that act as pro-oxidants and increase the existing ROS levels, thereby disturbing the ROS balance and tipping the cell machinery toward apoptotic cell death. Most conventional chemotherapeutic drugs induce cytotoxicity by raising intracellular ROS levels but pose the problem of nonselective killing of normal cells and development of drug resistance due to prolonged exposure., To assess the potential antiproliferative activity of anticancer agents, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay is used. Flow cytometry assays are used to examine the effects of anticancer agents on cell cycle and cell apoptosis. Western blot assays and real-time polymerase chain reaction are performed to confirm the apoptosis-associated signaling pathways caused by ROS generation, and ROS formation was monitored by fluorescence microscopy using the superoxide indicator dihydroethidium staining. Recently, several in vitro and in vivo models have been developed to study the role of ROS in the development of cancer, and to explore the utilities of ROS-mediated mechanisms in prevention and therapeutics of cancer diseases, which will be useful in anticancer agents' activity screening., Previously reported effects of anticancer agents on ROS are summarized in [Table 1].
|Table 1: Summary of the published works about anticancer agents act on reactive oxygen species|
Click here to view
| Conclusion|| |
In summary, an overproduction of ROS is observed in cancer cells, whereas it is underexpressed or absent in normal cells. Cancer cells depend heavily on the antioxidant defense system, and anticancer agents further increase cellular ROS levels by direct ROS generation. ROS generation in cancer cells contributes to the biochemical and molecular changes necessary for the tumor initiation, promotion, and progression, as well as tumor resistance to chemotherapy, thereby activating various ROS-induced cell death pathways, or inhibiting cancer cell resistance to chemotherapy is an alternative approach. Such results can be achieved using anticancer agents that either increase ROS generation, or inhibit antioxidant defense, or even a combination of both. In fact, some anticancer drugs used clinically or anticancer agents under clinical trials induce cancer cells death through enhancing ROS generation and/or impeding the antioxidant defense mechanism. In anticancer drugs screening, the elevation of ROS by anticancer agents can be used to achieve the selective killing of cancer cells, which is crucial in cancer cells apoptosis and death pathway. Hence, detecting the ROS levels is an effective method to evaluate their efficacy and attain our goal of screening more potent anticancer agents while studying the anticancer activity of targeted compounds.,,,,,,,,
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Wang Z, Yang HW, Wang X, Wang L, Cheng YD, Zhang YS, Tu YY. The molecular mechanism and regulatory pathways of cancer stem cells. Cancer Transl Med
2016; 2 (5): 147–53.
Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin
2016; 66 (2): 115–32.
Rebecca L, Kimberly D, Ahmedin J. Cancer statistics, 2016. CA Cancer J Clin
2016; 66 (1): 7–30.
Yarden Y, Caldes C. Basic cancer research: why it is essential for the future of cancer therapy. Bull Cancer
2014; 101 (9): E25–6.
Zang R, Zhang XD, Sun JX, Yang ST.In vitro
3-D multicellular models for cytotoxicity assay and drug screening. Process Biochem
2016; 51 (6): 772–80.
Ahmed K, Reddy VS, Santhosh V, Basha SA. Synthesis of (Z)-(arylamino)-pyrazolyl/isoxazolyl-2-propenones as tubulin targeting anticancer agents and apoptotic inducers. Org Biomol Chem
2015; 11 (13): 3416–31.
Gupta SC, Reuter S, Phromnoi K, Park B, Hema PS, Nair M, Aggarwal BB. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. J Biol Chem
2016; 291 (32): 16925–37.
Schumacker PT. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell
2015; 27 (2): 156–7.
Latella L, Sacco A, Pajalunga D, Tianen M, Macera D, D′Angelo M, Felici A, Sacchi A, Crescenzi M. Reconstitution of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle. Mol Cell Biol
2001; 21 (16): 5631–43.
Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: to promote or to suppress? Free Radic Biol Med
2017; 104 (1): 144–64.
Reczek CR, Chandel NS. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol
2017; 1 (1): 79–98.
He LZ, Lai HQ, Chen TF. Dual-function nanosystem for synergetic cancer chemo-radiotherapy through ROS-mediated signaling pathways. Biomaterials
2015; 51 (3): 30–42.
Kim W, Youn H, Kang C, Youn B. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis
2015; 20 (9): 1242–52.
Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep
2002; 3 (5): 420–5.
Zhang L, Zhang ZG, Chen F, Chen YZ, Lin Y, Wang J. Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways. Eur J Med Chem
2016; 123 (1): 226–35.
Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal
2012; 24 (5): 981–90.
Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several CDKs, numerous cyclins and diverse compensatory mechanisms. Oncogene
2009; 28 (33): 2925–39.
Zhang XH, Chen MX, Zou P, Kanchana K, Weng QY, Chen WB, Zhong P, Ji ZS, Zhou HP, He LC, Liang G. Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells. BMC Cancer
2015; 15 (3): 866–70.
Tong LY, Chuang CC, Wu SY, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Lett
2015; 367 (1): 18–25.
Feng XJ, Yu W, Zhou FF, Chen JJ, Shen PP. A novel small molecule compound diaporine inhibits breast cancer cell proliferation via promoting ROS generation. Biomed Pharmacother
2016; 83 (1): 1038–47.
Xiao W, Jiang Y, Men Q, Yuan L, Huang Z, Liu T, Li W, Liu X. Tetrandrine induces G1/S cell cycle arrest through the ROS/Akt pathway in EOMA cells and inhibits angiogenesis in vivo
. Int J Oncol
2015; 46 (1): 360–8.
Hong YS, Hong SW, KIm SM, Kim TW. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol
2012; 41 (1): 76–82.
Han BJ, Li W, Jiang GB, Lai SH, Zhang C, Zeng CC, Liu YJ. Effects of daidzein in regards to cytotoxicity in vitro
, apoptosis, reactive oxygen species level, cell cycle arrest and the expression of caspase and Bcl-2 family proteins. Oncol Rep
2015; 34 (3): 1115–20.
Verbon EH, Post JA, Boonstra J. The influence of reactive oxygen species on cell cycle progression in mammalian cells. Gene
2012; 511 (1): 1–6.
Croce CM, Reed JC. Finally, an apoptosis-targeting therapeutic for cancer. Cancer Res
2016; 76 (20): 5914–20.
Martin-Cordero C, Leon-Gonzalez AJ, Calderon-Montano JM, Burgos-Moron E, Lopez-Lazaro M. Pro-oxidant natural products as anticancer agents. Curr Drug Targets
2012; 13 (8): 1006–28.
Zhang M, Harashima N, Moritani T, Huang WD, Harada M. The roles of ROS and caspases in TRAIL-induced apoptosis and necroptosis in human pancreatic cancer cells. PLoS One
2015; 10 (5): e0127386.
Arumugam A, Subramani R, Nandy S, Powell S, Velazquez M, Orozco A, Galvez A, Lakshmanaswamy R. Desacetyl nimbinene inhibits breast cancer growth and metastasis through reactive oxygen species mediated mechanisms. Tumor Biol
2016; 37 (5): 6527–37.
Ma YC, Ke Y, Zi X, Zhao W, Shi XJ, Liu HM. Jaridonin, a novel ent-kaurene diterpenoid from Isodon rubescens
, inducing apoptosis via production of reactive oxygen species in esophageal cancer cells. Curr Cancer Drug Targets
2013; 13 (6): 611–24.
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol
2007; 35 (4): 495–516.
Cossarizza A, Franeschi C, Monti D, Salvioli S, Bellesia E, Rivabene R, Biondo L, Rainaldi G, Tinari A, Malorni W. Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res
1995; 220 (1): 232–40.
Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy aggarwal. Antioxid Redox Signal
2012; 16 (11): 1295–322.
Gibellini L, Pinti M, Milena N, Cossarizza A. Interfering with ROS metabolism in cancer cells: the potential role of quercetin. Cancers (Basel)
2010; 2 (2): 1288–311.
Taparia SS, Khanna A. Procyanidin-rich extract of natural cocoa powder causes ROS-mediated caspase-3 dependent apoptosis and reduction of pro-MMP-2 in epithelial ovarian carcinoma cell lines. Biomed Pharmacother
2016; 83 (1): 130–40.
Kang N, Jian JF, Cao SJ, Zhang Q, Mao YW, Huang YY, Peng YF, Qiu F. Physalin a induces G2/M phase cell cycle arrest in human non-small cell lung cancer cells: involvement of the p38 MAPK/ROS pathway. Mol Cell Biochem
2016; 415 (1): 145–55.
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov
2009; 8 (7): 579–91.
Maiti AK. Reactive oxygen species reduction is a key underlying mechanism of drug resistance in cancer chemotherapy. Chemother Open Access
2012; 1 (2): 1–5.
Su K, Wang CF, Zhang Y, Cai YJ, Zhang YY, Zhao Q. The inhibitory effects of carnosic acid on cervical cancer cells growth by promoting apoptosis via ROS-regulated signaling pathway. Biomed Pharmacother
2016; 82 (1): 180–92.
Lu WQ, Ogasawara M, Huang P. Models of reactive oxygen species in cancer. Drug Discov Today Dis Models
2007; 4 (2): 67–73.
Thomas RM, Dyke TV, Merlino G, Day CP. Concepts in cancer modeling: a brief history. Cancer Res
2016; 76 (20): 5921–5.
Yi L, Yuan ZY, Cheng G, Lingyun Z, Guilian Y, Wei G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci
2015; 105 (5): 520–7.
Miki H, Uehara N, Kimura A, Sasaki T, Yuri T, Yoshizawa K, Tsubura A. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int J Oncol
2012; 40 (4): 1020–8.
Al Dhaheri Y, Attoub S, Ramadan G, Arafat K, Bajbouj K, Karuvantevida N, AbuQamar S, Eid A, Iratni R. Carnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer. PLoS One
2014; 9 (10): e109630.
Ghosh P, Singha Roy S, Basu A, Bhattacharjee A, Bhattacharya S. Sensitization of cisplatin therapy by a naphthalimide based organoselenium compound through modulation of antioxidant enzymes and p53 mediated apoptosis. Free Radic Res
2015; 49 (4): 453–71.
Yuan X, Zhang B, Chen N, Chen XY, Liu LL, Zheng QS, Wang ZP. Isoliquiritigenin treatment induces apoptosis by increasing intracellular ROS levels in HeLa cells. J Asian Nat Prod Res
2012; 14 (8): 1477–2213.
Lo YL, Wang WJ. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro
. Chem Biol Interact
2013; 205 (3): 188–97.
Choi YJ, Hwang SG, Um HD, Park JK. Abstract 3343: podophyllotoxin acetate (PA) enhancing γ-ionizing radiation-induced apoptosis via the ROS/p38/caspase pathway. Cancer Res
2015; 75 (15): 3343–7.
Meshkini A, Yazdanparast R. Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol
2012; 64 (4): 357–65.
Huang Z, Xu Y, Peng W. Colchicine induces apoptosis in HT-29 human colon cancer cells via the AKT and c-Jun N-terminal kinase signaling pathways. Mol Med Rep
2015; 12 (4): 5939–44.